Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 1877 of 6351
-
Nerve block may help septic Patients' organs recover
Disease control Recruiting nowThis study is a prospective, multicenter, parallel-group, open-label, randomized controlled clinical trial. Sepsis is defined as organ dysfunction induced by infections. And sepsis and gastrointestinal injury can be the leading cause for each other. Our previous study showed erec…
Sponsor: Jing Cai, MD • Aim: Disease control
Last updated Jun 26, 2026 14:34 UTC
-
A dissolving scaffold may help camouflage a sunken chest
Disease control OngoingThe clinical study evaluates the use of a custom-made medical-grade polycaprolactone-PCL Pectus scaffold implantation with Autologous Fat Grafting for pectus excavatum camouflage (IT). The study aims to demonstrate the safety and clinical performance of the insertion of an absorb…
Sponsor: BellaSeno GmbH • Aim: Disease control
Last updated Aug 01, 2026 00:00 UTC
-
New combo therapy shows promise for rare gut tumors
Disease control OngoingThe phase I objective of this study is to establish the maximal tolerated dose (MTD) of cabozantinib in 20 mg, 40 mg and 60 mg dose escalation cohorts in combination with Lu-177 dotatate at a standard dose of 7.4 GBq in four (4) 8-week cycles followed by continuation cabozantinib…
Phase 1 • Sponsor: Providence Health & Services • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
New drug combo offers hope for rare penile cancer
Disease control Recruiting nowThe purpose of the study is to evaluate the efficacy and safety of the combination of niraparib and dostarlimab in patients participants with advanced relapsed/refractory penile cancer.
Phase 2 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
New drug combo aims to slow advanced breast cancer
Disease control OngoingAnalysis of circulating tumour DNA (ctDNA) found in a patient's peripheral blood can identify cancer progression and predict a patient's response to therapy. By using ctDNA analysis and imaging techniques, the FAIM trial aims to determine whether the addition of the experimental …
Phase 2 • Sponsor: Royal Marsden NHS Foundation Trust • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
Immune cell army targets Hard-to-Treat throat cancer
Disease control Recruiting nowThis study was a single-arm, open-label, "3 + 3" dose-escalation Exploratory research. The patients were divided into two groups: EBV TCR-T-cell Group and EBV CAR-T-cell group. The EBV CAR-T-treated group received three progressively increasing dose levels (3.0 × 106 cells/kg, 9.…
Early phase 1 • Sponsor: Fudan University • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
New study aims to stop Post-Birth bleeding with smarter drug dosing
Prevention Recruiting nowIn part 1 of the study, the investigators conducted a prospective, open-label, dose finding pharmacokinetic (PK) study in 43 pregnant 3rd trimester women scheduled for non-emergent cesarean section. The investigators administered three doses of the drug (5 mg/kg, 10 mg/kg and 15…
Phase 2 • Sponsor: Inova Health Care Services • Aim: Prevention
Last updated Jun 27, 2026 12:01 UTC
-
New combo aims to keep advanced lung cancer in check
Disease control Recruiting nowThis is a phase II study to assess the efficacy, safety, and Health Related Quality of Life (HRQoL) of combination cabozantinib and pembrolizumab as maintenance therapy for patients with metastatic squamous Non Small Cell Lung Cancer(sqNSCLC) who have received 4 cycles of inducti…
Phase 2 • Sponsor: University of Illinois at Chicago • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
New pill could stop dangerous swelling attacks in hereditary angioedema
Symptom relief By invitation onlyThis study evaluates the safety and efficacy of long-term on-demand treatment with orally administered deucrictibant for acute hereditary angioedema (HAE) attacks, including laryngeal attacks. The study will enroll participants from Study PHA022121-C201 (NCT04618211), Study PHA02…
Phase 2/3 • Sponsor: Pharvaris Netherlands B.V. • Aim: Symptom relief
Last updated Jul 23, 2026 00:00 UTC
-
New eye drug 601 shows promise in major trial for blurry vision
Disease control CompletedTo compare the efficacy and safety of recombinant humanized anti-VEGF monoclonal antibody (601) with Ranibizumab in patients with macular edema secondary to BRVO
Phase 3 • Sponsor: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
Blood test may spot kidney cancer return before scans do
Knowledge-focused Recruiting nowTo conduct prospective studies to confirm the value of circulating tumor DNA and its abnormal methylation in longitudinal monitoring of patients undergoing kidney cancer surgery.
Sponsor: Jinling Hospital, China • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:03 UTC
-
Bone drugs may double as liver fat fighters — a trial puts them to the test
Disease control CompletedNonalcoholic fatty liver disease (NAFLD) is a chronic, metabolic liver disease that is closely related to obesity, type 2 diabetes mellitus (T2DM) and metabolic syndrome (MetS) in a bidirectional mode. NAFLD affects approximately 25% of the worldwide population. NAFLD refers to a…
Phase 4 • Sponsor: Aristotle University Of Thessaloniki • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
Ultrasound 'Tissue Stiffness' test could reveal hidden rotator cuff healing problems
Knowledge-focused CompletedThis exploratory project will evaluate the biomechanical and functional intermediate-term outcome (2 to 5 years) after arthroscopic rotator cuff repair (ARCR) with modern non-invasive ultrasound techniques (especially shear wave elastography (SWE)), standardized physical examinat…
Sponsor: University Hospital, Basel, Switzerland • Aim: Knowledge-focused
Last updated Aug 23, 2026 00:00 UTC
-
New radioactive drug takes aim at Hard-to-Treat cancers
Disease control Recruiting nowA Phase 1 Open-Label, First-in-human, Dose Escalation and Expansion Study to Determine the Safety, Tolerability, Dosimetry, Pharmacokinetics, and Preliminary Efficacy of 212Pb-DOTAM-GRPR1 in Adult Participants with Recurrent or Metastatic GRPR-expressing Tumors
Phase 1 • Sponsor: Orano Med Theranostics, SAS • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
Light therapy tested for painful mouth sores after stem cell transplant
Symptom relief Recruiting nowThe purpose of this study is to find out whether photobiomodulation/PBM therapy using the Thor LX2.3 therapy system is a safe and effective treatment for oral Graft-Versus-Host Disease/GVHD.
Phase 2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Symptom relief
Last updated Jun 27, 2026 12:36 UTC
-
Brain training targets impulse control to fight OCD and related disorders
Disease control Recruiting nowThe impaired ability to suppress an inappropriate but pre-potent response (response inhibition; RI) characterizes several debilitating clinical problems, including obsessive-compulsive and related disorders (OCRD) such as obsessive-compulsive disorder, trichotillomania, and skin …
Sponsor: University of Wisconsin, Milwaukee • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Experimental pill takes on advanced cancers alongside immunotherapy
Disease control CompletedThe purpose of this study is to assess the efficacy and safety and establish a preliminary recommended Phase 2 dose (RP2D) of MK-6598 administered as monotherapy and in combination with pembrolizumab (MK-3475) in adult participants with advanced or metastatic solid tumors.
Phase 1 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jul 17, 2026 00:00 UTC
-
New drug SLC-3010 takes on advanced solid tumors
Disease control Stopped earlyThis is a Phase 1/2, open-label, multicenter, dose escalation and expansion study, evaluating the safety, tolerability, pharmacokinetic, preliminary anti-tumor activity, and effects on pharmacodynamic markers following administration of SLC-3010 as monotherapy and in combination …
Phase 1/2 • Sponsor: Selecxine • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
AI-Powered heart scans could predict heart attacks before they strike
Knowledge-focused Recruiting nowThe goal of this observational study is to learn if AI-assisted cardiac CT imaging can improve cardiovascular risk stratification and prediction of future coronary events in an adult population undergoing clinically indicated cardiac CT. The main questions it aims to answer are:…
Sponsor: University of Galway • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:31 UTC
-
New drug AZD9592 enters first human trials for tough cancers
Disease control OngoingThis is a first-in-human (FIH) Phase I, multi-center, open-label, study of AZD9592, in patients with advanced solid tumors. The study consists of several study modules, each evaluating the safety, tolerability, preliminary efficacy, pharmacokinetics (PK), pharmacodynamics, anti-t…
Phase 1 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC